TD Cowen analyst Charles Rhyee maintained a Buy rating on BrightSpring Health Services, Inc. today and set a price target of $42.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Charles Rhyee has given his Buy rating due to a combination of factors including BrightSpring Health Services’ strong fundamentals and promising outlook for 2026. Despite some short-term momentum possibly stalling after a significant increase in share price, the company remains well-positioned with robust performance in its pharmaceutical segment. The company has shown consistent growth, with mid-teens EBITDA growth anticipated, which is higher than the consensus estimate.
BrightSpring Health Services has demonstrated strong performance in its specialty and infusion revenues, with significant year-over-year increases. The management’s positive outlook for 2026, driven by continued specialty strength and stable to slightly increasing pharmaceutical margins, further supports the Buy rating. The company’s ability to exceed expectations in total, pharmacy, and provider EBITDA also highlights its operational strength, making it a compelling investment opportunity according to Rhyee.
In another report released on October 23, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $36.00 price target.